Author Bio
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian s investing strategy is to buy high-quality companies and then let compounding work its magic.
See all of his articles here.Follow @brianferoldi
In this episode of
Industry Focus: Wildcard, host Emily Flippen is joined by Motley Fool contributor Brian Feroldi as he walks you through three small-cap healthcare companies that may have flown under your radar with the aim of answering the question every investor wants to know: Can this business result in 10x returns?
To catch full episodes of all The Motley Fool s free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.
RMA of Connecticut Launches INVOCELL®, An Innovative, Proven Fertility Treatment Option
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
RMA of Connecticut Launches INVOCELL®, An Innovative, Proven Fertility Treatm ( NORWALK )
bio-medicine.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bio-medicine.org Daily Mail and Mail on Sunday newspapers.
Celebrate The 4th Of July With An Arts Binge Around New York City
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Autism spectrum disorder (ASD) has increased over tenfold over the past several decades and appears predominantly associated with paternal transmission. Although genetics is anticipated to be a component of ASD etiology, environmental epigenetics is now also thought to be an important factor. Epigenetic alterations, such as DNA methylation, have been correlated with ASD. The current study was designed to identify a DNA methylation signature in sperm as a potential biomarker to identify paternal offspring autism susceptibility. Sperm samples were obtained from fathers that have children with or without autism, and the sperm then assessed for alterations in DNA methylation. A genome-wide analysis (> 90%) for differential DNA methylation regions (DMRs) was used to identify DMRs in the sperm of fathers (n = 13) with autistic children in comparison with those (n = 13) without ASD children. The 805 DMR genomic features such as chromosomal location, CpG densit